Established and emerging invasive mycoses

Infectious Diseases in Clinical Practice

Volumn 7, Issue SUPPL. 1, 1998, Pages

  Dismukes, William E ^a,b  

^a University of Alabama at Birmingham   (United States)

^b Division of Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDIASIS; FUSARIUM; HUMAN; INFECTION RISK; MYCOSIS; PATHOGENESIS; PHAEOHYPHOMYCOSIS; REVIEW; TRICHOSPORON;

EID: 0031895803     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019048-199803000-00006     Document Type: Review

References (31)

1. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996;22(2 Suppl):89S-94S.
2. Pfaller M, Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992;11:287-91.
3. Perfect JR, Schell WA. The new fungal opportunists are coming. Clin Infect Dis 1996;22(2 Suppl):112S-118S.
4. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.
5. Walsh TJ. Trichosporonosis. Infect Dis Clin North Am 1989;3:43-52.
6. Hajjeh RA, Blumberg HM. Bloodstream infection due to Trichosporon beigelii in a burn patient: case report and review of therapy. Clin Infect Dis 1995;20:913-6.
7. Martino P, Vendiffi M, Micozzi A, et al. Blastoschizomyces capitatus: an emerging cause of invasive fungal disease in leukemia patients. Rev Infect Dis 1990;12:570-2.
8. Anaissie E, Kantarjian H, Ro J, et al. The emerging role of Fusarium infections in patients with cancer. Medicine (Baltimore) 1988;67:77-83.
9. Martino P, Gustaldi R, Raccah R, et al. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect 1994;28(1 Suppl):7-15.
10. Orth B, Frei R, Itin PH, et al. Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion. Ann Intern Med 1996;125:799-806.
11. Rossmann SN, Cernoch PL, Davis JR. Dematiaceous fungi are an increasing cause of human disease. Clin Infect Dis 1996;22:73-80.
12. Singh N, Chang FY, Gayowski T, et al. Infections due to dematiaceous fungi in organ transplant recipients case report and review. Clin Infect Dis 1997;24:369-74.
13. Beck-Sague CM, Jarvis WR, the National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167:1247-51.
14. Banerjee SN, Emori TG, Culver DH, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991;91(3B Suppl): 865-895.
15. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-42.
16. Wey SB, Mori M, Pfaller MA, et al. Risk factors for hospital acquired candidemia: a matched case-control study. Arch Intern Med 1989;149:2349-53.
17. Komshian SV, Uwaydah AK, Sobel JD, et al. Fungemia caused by Candida species and Tomlopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-90.
18. Bross J, Talbot GH, Maislin G, et al. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989;87:614-9.
19. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984;100:345-51.
20. Wingard JR, Beals SU, Santos GW, et al. Aspergillus infections in bone marrow transplant recipients. Bone Marrow Transplant 1987;2:175-81.
21. Burch PA, Karp JE, Merz WG, et al. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol 1987;5:1985-93.
22. Saral R. Candida and aspergillus infections in immunocompromised patients. Rev Infect Dis 1991;13:-487-92.
23. McWhinney PH, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17:397-404.
24. Guiot HFI, Fibbe WE, van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994;18:525-32.
25. Wey SB, Mori M, Pfaller MA, et al. Hospital acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
26. Fraser VJ, Jones M, Dunkel J, et al. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis 1992;15:414-21.
27. Price MF, LaRocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a five-year period. Antimicrob Agents Chemother 1994;38:1422-4.
28. Weinstein MP, Towns MI, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997;24:584-602.
29. Nguyen MH, Peacock JE Jr, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.
30. Guarro J, Gene J. Opportunistic fusarial infections in humans. Eur J Clin Microbiol Infect Dis 1995;14:741-54.
31. Anaissie E, Gokaslan E, Hachem R, et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 1992;15:781-7.